Community Investing Ideas

Global Weekly Picks

US$395
FV
6.5% undervalued intrinsic discount
10.63%
Revenue growth p.a.
3.3k
users have viewed this narrative
23users have liked this narrative
3users have commented on this narrative
25users have followed this narrative
US$30
FV
1.2k% overvalued intrinsic discount
-28.34%
Revenue growth p.a.
5k
users have viewed this narrative
25users have liked this narrative
7users have commented on this narrative
31users have followed this narrative
US$1.48k
FV
35.4% undervalued intrinsic discount
18.00%
Revenue growth p.a.
2k
users have viewed this narrative
5users have liked this narrative
0users have commented on this narrative
16users have followed this narrative
LUCD logo
Lucid Diagnostics

Poised for success

Lucid Diagnostics' EsoGuard is a novel screening tool for esophageal cancer. It is relatively non-invasive and may become widely accepted soon.Read more

View narrative
7
users have viewed this narrative
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
US$5
77.0% undervalued intrinsic discount
Fair Value
Profit Margin
13.44%
Future PE
24.75x
Price in 2031
US$7.33
RM 0.17
20.6% undervalued intrinsic discount
Fair Value
Revenue
20% p.a.
Profit Margin
5.91%
Future PE
24.17x
Price in 2031
RM 0.24
US$300
27.1% overvalued intrinsic discount
Fair Value
Revenue
13.98% p.a.
Profit Margin
4%
Future PE
351.39x
Price in 2031
US$487.3
US$11.98
23.5% undervalued intrinsic discount
Fair Value
Revenue
5% p.a.
Profit Margin
10%
Future PE
21x
Price in 2031
US$19.29
US$134.63
28.3% undervalued intrinsic discount
Fair Value
Revenue
6.5% p.a.
Profit Margin
13%
Future PE
20x
Price in 2031
US$207.14